Myeloma Market Snapshot: New Drug Classes On The Way, But Cost Could Be A Problem

More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.

• Source: Shutterstock

When it comes to immunotherapy, multiple myeloma has been a relative latecomer. The first immunotherapy for the second most common blood cancer, Bristol Myers Squibb Company and 2seventy Bio, Inc.’s BCMA-directed CAR-T therapy Abecma (idecabtagene vicleucel), received US Food and Drug Administration approval in 2021, seven years after the introduction of PD-1 checkpoint inhibitors. But now the immunotherapy field for multiple myeloma is exploding, with a plethora of agents targeting BCMA along with more novel targets like GPRC5D and FcRH5. Outside of immunotherapy, BMS’s cereblon E3 ligase modulator (CELMoD) class is in Phase III development.

The range of new therapies coming down the pike means more options than ever for multiple myeloma patients. But the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Snapshot

IgAN Market Snapshot: Growing Market, But Patient Segmentation Still A Question

 

IgA nephropathy has gone from having zero to three approved treatments in just a few years, with over half a dozen more in late-stage development. But there are still many unknowns.

Atopic Dermatitis Market Snapshot: A Crowded Field With Room To Grow

 

Topical, oral and biologic drugs have made a difference for patients with atopic dermatitis, but full control remains elusive for many, with the heterogeneous condition, leaving open a door for new medications.

Myeloma Market Snapshot: New Drug Classes On The Way, But Cost Could Be A Problem

 

More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.

Myeloma Market Snapshot: Backlogs Dog BCMA CAR-Ts As Treatment Paradigm Evolves

 

KOLs told Scrip about how they are incorporating new immunotherapies into treatment and combining existing agents, but some new drug classes have struggled to take root.

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.